Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Breast Cancer Therapeutics Pipeline Analysis Market Expected to Reach USD 7.8 Billion at a CAGR of 58.3% From 2015 to 2023: Transparency Market Research


News provided by

Transparency Market Research

11 Aug, 2015, 12:30 GMT

Share this article

Share toX

Share this article

Share toX

ALBANY, New York, August 11, 2015 /PRNewswire/ --

According to a new market research report published by Transparency Market Research "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023", the global breast cancer therapeutics market was valued at USD 55.5 million in 2015 and is estimated to reach USD 7,853.1 million in 2023 at a CAGR of 58.3% from 2015 to 2023.

Browse Market Research Report on Breast Cancer Therapeutics: Pipeline Analysis Market: 

http://www.transparencymarketresearch.com/breast-cancer-therapeutics-pipeline-analysis-market.html

Cancer is a disease in which abnormal cells grow out of control and invade other normal cells of the body. According to the World Health Organization (WHO), there are more than 200 types of cancer, accounting for over 14.1 million new cases globally every year. Breast cancer is the second most prevalent type of cancer worldwide. According to the World Cancer Research Fund International, breast cancer is the most common cancer in women worldwide, with nearly 1.7 million cases diagnosed in 2012. Rising prevalence of breast cancer is one of the major factor driving the growth of effective and novel therapies. Globally, breast cancer is the most common invasive cancer in women. Nearly 1.7 million new cases of breast cancer were diagnosed in 2013. Breast cancer is the second most common cause of death in women in the U.S., after lung cancer. According to the American Cancer Society, an estimated 231,840 women would be diagnosed with breast cancer in 2015 in the U.S. alone. A report published by the International Agency for Research on Cancer stated that 458,337 incidences of breast cancer in women were recorded in Europe in 2012. Belgium had the highest rate of breast cancer, followed by Denmark and France.

Get Sample Report Copy of Breast Cancer Therapeutics: Pipeline Analysis Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5678

Incidence rates of breast cancer are much higher in developed countries compared to developing countries. Oral contraceptives and hormone replacement therapy, excessive alcohol consumption, not having children or having children at an older age, obesity, smoking, and sedentary lifestyle are the major risk factors that could cause breast cancer. Hence, incidence rates of breast cancer are highest in developed countries where the prevalence of these risk factors is much greater. According to the Breast Cancer Organization, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S. in 2015, along with 60,290 new cases of non-invasive (in situ) breast cancer and about 2,350 new cases of invasive breast cancer in men. The survival rate of the patients with cancer depends upon the stage in which the cancer is diagnosed.

Browse Press Release of Breast Cancer Therapeutics: Pipeline Analysis Market: http://www.transparencymarketresearch.com/pressrelease/breast-cancer-therapeutics-pipeline-analysis-market.htm

The pipeline of breast cancer is strong and rich in number of research molecules especially in phase I and phase II clinical studies. Drugs currently in phase III clinical trials are NKTR-102 (Nektar Therapeutics), DOXIL (Johnson & Johnson Pharmaceutical Research & Development, L.L.C), and trastuzumab emtansine + pertuzumab (Hoffmann-La Roche AG), BKM120 (Novartis).

Among all the pipeline drugs in phase III, Neratinib (Puma Biotechnology, Inc.) is estimated to generate maximum revenue by 2023. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, or EGFRs, HER1, HER2, and HER4. Palbociclib + Fulvestrant (Pfizer, Inc.) is estimated to be the second most promising drug and is expected to provide promising therapeutic results in the treatment of breast cancer. Palbociclib is an investigational drug and an oral targeted agent that selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 in order to regain cell cycle control and inhibit proliferation of tumor cells. The pipeline of breast cancer therapeutics is expected to generate significant revenue after commercialization primarily due to rising prevalence of breast cancer and associated mortality globally. Existing manufacturers and new entrants are therefore recommended to focus on the key growth areas and capitalize on the potential growth opportunities.

Other Reports Published by Transparency Market Research:  

  • Kidney Cancer Drugs Market: http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
  • Dyslipidemia Drugs Market: http://www.transparencymarketresearch.com/dyslipidemia-market.html
  • Peptide Therapeutics Market: http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

Key players in the breast cancer pipeline market are Pfizer, Inc., Puma Biotechnology, Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and F. Hoffmann-La Roche AG. However, the therapeutic pattern is shifting from traditional chemotherapy to biological treatment.

Browse Upcoming Market Research Reports:  

  • Hormone Refractory Breast Cancer Market: http://www.transparencymarketresearch.com/hormone-refractory-breast-cancer-market.html
  • Predictive Breast Cancer Gene Testing Market: http://www.transparencymarketresearch.com/predictive-breast-cancer-gene-testing.html

The global breast cancer therapeutics market has been segmented into:

Global Breast Cancer Therapeutics Market: Pipeline Analysis, by Drugs (Phase III) 

  • Palbociclib (PD-0332991) + Exemestane
  • NK105
  • BKM120
  • NKTR-102
  • Neratinib
  • Olaparib
  • DOXILs
  • ABP 980
  • CT-P6
  • Trastuzumab emtansine
  • Phase II Drug Candidates
  • Phase I Drug Candidates

Browse All Other Pharmaceutical Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us:  

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:
Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.